Corneal and scleral involvement in inflammatory rheumatic disease: Rheumatologists and ophthalmologists exchanging views.
Arthritis, Rheumatoid
/ diagnosis
Comorbidity
Corneal Ulcer
/ diagnosis
Female
Glucocorticoids
/ therapeutic use
Humans
Immunosuppressive Agents
/ therapeutic use
Interprofessional Relations
Keratitis
/ diagnosis
Male
Ophthalmologists
Prevalence
Prognosis
Rheumatologists
Scleritis
/ diagnosis
Treatment Outcome
Inflammatory joint disease
Peripheral ulcerative keratitis
Rheumatoid arthritis
Scleritis
Treatment
Journal
Joint bone spine
ISSN: 1778-7254
Titre abrégé: Joint Bone Spine
Pays: France
ID NLM: 100938016
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
accepted:
13
12
2018
pubmed:
4
2
2019
medline:
24
6
2020
entrez:
4
2
2019
Statut:
ppublish
Résumé
Corneal and scleral disorders related to inflammatory rheumatic diseases vary both in frequency and in severity. Sicca syndrome and its complications are the most common ocular manifestations and, together with episcleritis, can usually be managed by topical treatments. In contrast, the various forms of scleritis and peripheral ulcerative keratitis generally require systemic glucocorticoid therapy and the initiation or intensification of immunosuppressive treatment. Corneal and scleral manifestations are inaugural in a few patients with chronic inflammatory rheumatic disease. No direct information is available on the frequency of severe corneal and scleral involvement, which can only be estimated by extrapolating data from case-series or cohorts, many of which are historical. Similarly, given the absence of randomized controlled trials, treatment decisions must rely on clinical experience acquired in referral centers and on reports of small case-series studies. The rheumatologist and ophthalmologist must work closely together to ensure the prompt and optimal management of these potentially serious conditions.
Identifiants
pubmed: 30711694
pii: S1297-319X(19)30012-0
doi: 10.1016/j.jbspin.2019.01.014
pii:
doi:
Substances chimiques
Glucocorticoids
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
699-705Informations de copyright
Copyright © 2019 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.